Logo

Allelica Ancestry-Specific Polygenic Risk Score Tests for Common Diseases

Sep 21, 2022

Allelica now offers ancestry-specific polygenic risk score (PRS) analysis for coronary artery disease, breast cancer, prostate cancer, type 2 diabetes, and Alzheimer's disease as lab-developed tests in partnership with Clinical Enterprise, a CLIA-certified, CAP-accredited laboratory located in Framingham, Massachusetts. These can be ordered as standalone single-PRS tests or as panels with multiple PRSs. Allelica plans to include more diseases across cardiology, oncology, and women's health in future offerings. DNA from patient saliva forms the input for a microarray genotyping analysis carried out by Clinical Enterprise. The output of that analysis feeds into Allelica's platform, which calculates ancestry-specific PRSs and generates clinical-grade reports via proprietary algorithms. Reports are also available as a white-label package, delivered to providers through a secure portal or through integration with electronic medical records.

Breaking News
The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.